GlassScriptPhysician profile
Bernadette A Demuri
NPI 1003831959
$9,059.02
in general payments reported to CMS, 2019-2025
14 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,195 · 2020: $218 · 2021: $121 · 2022: $816 · 2023: $377 · 2024: $4,097 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,570 · Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,570.00 |
| Food and Beverage | $1,138.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,720.41 | 2019-2024 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,287.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $800.73 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $334.26 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.34 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $316.54 | 2019-2021 | |
| Alkermes, INC. | $292.49 | 2022-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $275.18 | 2023-2024 | Qelbree |
| Neurocrine Biosciences, INC. | $232.93 | 2022-2024 | Ingrezza |
| Livanova USA, INC. | $209.33 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Axsome Therapeutics, INC. | $155.45 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $74.22 | 2019 | |
| Neuronetics, INC. | $15.10 | 2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Demuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.